Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:Overviews of contentious or emerging issues.Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes.In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area.Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.Editorials and commentaries on topical issues.Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.
《药物安全》是国际药物警戒学会的官方期刊。期刊内容包括:有争议或新出现问题的概述;全面的叙述性综述,提供流行病学、临床特征、个别药物和药物类别不良反应的预防和管理的权威信息来源;对某一药物在特定治疗领域的不良反应和疗效数据进行深入的获益风险评估;系统综述(有或无荟萃分析),使用PRISMA声明中概述的明确、系统的方法,整理经验证据以回答特定的研究问题;原创研究文章,报告药物流行病学、药物警戒、药理学和毒理学以及药物基因组学等学科精心设计的研究结果;专题问题的社论和评论。其他数字功能(包括动画摘要、视频摘要、幻灯片、音频幻灯片、教学视频、信息图表、播客和动画)可与文章一起发表;目的是提高刊物的知名度、读者群和教育价值。此外,发表在《药物安全性和药物》上的文章可能附有简明扼要的摘要,以帮助对该领域有一定了解但没有深入专业知识的读者了解重要的医学进展。
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
来源期刊:Drug SafetyDOI:10.1007/s40264-018-0778-4
Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00800-x
Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance
来源期刊:Drug SafetyDOI:10.1007/s40264-018-00791-1
Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case–Control Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00837-y
The Impact of Litigation-Associated Reports on Signal Identification in the US FDA’s Adverse Event Reporting System
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00834-1
Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00836-z
Development and First Use of the Patient’s Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit–Harm of Drugs Received During Clinical Studies
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00877-4
Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00852-z
Use of FDA’s Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00798-2
Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00847-w
Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00867-6
Correction to: A Machine-Learning Algorithm to Optimise Automated Adverse Drug Reaction Detection from Clinical Coding
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00820-7
Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00882-7
The Role of Unit-Dose Child-Resistant Packaging in Unintentional Childhood Exposures to Buprenorphine–Naloxone Tablets
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00883-6
Correction to: Implications of Individual QT/RR Profiles—Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00802-9
Fatal Toxicity Indices for Medicine-Related Deaths in New Zealand, 2008–2013
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00885-4
Medical Devices: Classification and Analysis of Faults Leading to Harms
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00879-2
Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00844-z
The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New Discoveries
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00818-1
The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00892-5
Correction to: vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues
来源期刊:Drug SafetyDOI:10.1007/s40264-019-00803-8